Register

Institutional Sign In

Go
Home » Companies » Pharmaceutical in Czechia » Bayer Czech Republic

Bayer Czech Republic

Bayer CR's Cash & Cash Equivalents rose 94.1% yoy to CZK 10.8 mil in 2017

By Helgi Library - April 2, 2020

Bayer Czech Republic's total assets reached CZK 1,165 mil at the end of 2017, down 3.71% compared to the previous year. ...

Annual Quarterly
Profit Statement 2015 2016 2017
Sales CZK mil 4,277 4,326 4,180
Gross Profit CZK mil 592 621 487
EBITDA CZK mil 168 233 158
EBIT CZK mil 164 228 151
Financing Cost CZK mil 1.58 3.82 4.04
Pre-Tax Profit CZK mil 162 224 147
Net Profit CZK mil 123 175 106
Dividends CZK mil 60.0 50.0 ...
Balance Sheet 2015 2016 2017
Total Assets CZK mil 830 1,210 1,165
Non-Current Assets CZK mil 16.1 16.1 13.6
Current Assets CZK mil 810 1,190 1,145
Working Capital CZK mil 463 1,016 984
Shareholders' Equity CZK mil 246 361 417
Liabilities CZK mil 584 849 748
Total Debt CZK mil 151 467 404
Net Debt CZK mil 150 461 393
Ratios 2015 2016 2017
ROE % 50.6 57.6 27.2
ROCE % 29.0 23.1 10.4
Gross Margin % 13.8 14.3 11.6
EBITDA Margin % 3.93 5.38 3.77
EBIT Margin % 3.83 5.27 3.62
Net Margin % 2.89 4.04 2.53
Net Debt/EBITDA 0.890 1.98 2.49
Net Debt/Equity % 60.8 128 94.4
Cost of Financing % 1.76 1.24 0.929
Cash Flow 2015 2016 2017
Total Cash From Operations CZK mil ... -247 122
Total Cash From Investing CZK mil ... -4.84 -3.60
Total Cash From Financing CZK mil ... 256 -113
Net Change In Cash CZK mil ... 4.64 5.25
Cash Conversion Cycle days 40.3 93.0 91.9
Cash Earnings CZK mil 128 180 112
Free Cash Flow CZK mil ... -251 118

Get all company financials in excel:

Download Sample   $19.99

summary Unit 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
income statement                              
Sales CZK mil                 3,344 3,245 3,438 4,054 4,277    
Gross Profit CZK mil                 1.69 372 451 499 592    
EBIT CZK mil                 160 104 128 139 164    
Net Profit CZK mil                 166 83.4 96.2 107 123    
ROE %                 34.8 22.3 33.5 40.5 50.6    
EBIT Margin %                 4.77 3.22 3.72 3.43 3.83    
Net Margin %                 4.96 2.57 2.80 2.64 2.89    
Employees                 184 170 178 181 187    
balance sheet                              
Total Assets CZK mil                 774 572 698 682 830    
Non-Current Assets CZK mil                 70.6 30.5 17.1 15.2 16.1    
Current Assets CZK mil                 698 539 678 662 810    
Shareholders' Equity CZK mil                 460 289 286 243 246    
Liabilities CZK mil                 314 283 413 440 584    
Non-Current Liabilities CZK mil                 7.97 3.22 0 0 0    
Current Liabilities CZK mil                 306 280 410 426 522    
Net Debt/EBITDA                 -0.298 -0.098 0.140 0.150 0.890    
Net Debt/Equity %                 -10.9 -3.80 6.64 8.88 60.8    
Cost of Financing % ... ... ... ... ...     ... ... ... 11.0 6.28 1.76    
cash flow                              
Total Cash From Operations CZK mil             ... ... ... ... ... ... ...    
Total Cash From Investing CZK mil             ... ... ... ... ... ... ...    
Total Cash From Financing CZK mil             ... ... ... ... ... ... ...    
Net Change In Cash CZK mil             ... ... ... ... ... ... ...    
income statement Unit 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
income statement                              
Sales CZK mil                 3,344 3,245 3,438 4,054 4,277    
Cost of Goods & Services CZK mil                 3,342 2,873 2,987 3,555 3,684    
Gross Profit CZK mil                 1.69 372 451 499 592    
Staff Cost CZK mil                 250 243 277 297 324    
Other Cost CZK mil                 -416 17.0 38.3 59.0 100    
EBITDA CZK mil                 168 112 135 143 168    
Depreciation CZK mil                 7.96 7.87 7.63 4.06 4.42    
EBIT CZK mil                 160 104 128 139 164    
Financing Cost CZK mil                 -35.4 2.33 4.94 3.72 1.58    
Extraordinary Cost CZK mil                 0 0 0 0 0    
Pre-Tax Profit CZK mil                 195 102 123 135 162    
Tax CZK mil                 29.1 18.6 26.7 28.3 38.7    
Minorities CZK mil                 0 0 0 0 0    
Net Profit CZK mil                 166 83.4 96.2 107 123    
Dividends CZK mil                 0 100 150 120 60.0   ...
growth rates                              
Total Revenue Growth % ...               -2.02 -2.94 5.93 17.9 5.49    
Operating Cost Growth % ...               -158 -257 21.4 12.8 19.2    
EBITDA Growth % ...               -0.531 -33.0 20.7 5.62 17.5    
EBIT Growth % ...               6.82 -34.6 22.5 8.75 17.7    
Pre-Tax Profit Growth % ...               27.9 -47.7 20.5 10.1 19.8    
Net Profit Growth % ...               39.4 -49.7 15.3 11.2 15.4    
ratios                              
ROE %                 34.8 22.3 33.5 40.5 50.6    
ROCE % ...               170 27.1 26.9 28.9 29.0    
Gross Margin %                 0.050 11.5 13.1 12.3 13.8    
EBITDA Margin %                 5.01 3.46 3.94 3.53 3.93    
EBIT Margin %                 4.77 3.22 3.72 3.43 3.83    
Net Margin %                 4.96 2.57 2.80 2.64 2.89    
Payout Ratio %                 0 120 156 112 48.6   ...
Cost of Financing % ... ... ... ... ...     ... ... ... 11.0 6.28 1.76    
Net Debt/EBITDA                 -0.298 -0.098 0.140 0.150 0.890    
balance sheet Unit 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
balance sheet                              
Non-Current Assets CZK mil                 70.6 30.5 17.1 15.2 16.1    
Property, Plant & Equipment CZK mil                 24.1 20.0 16.7 14.7 15.1    
Intangible Assets CZK mil                 3.24 1.05 0.395 0.504 1.01    
Current Assets CZK mil                 698 539 678 662 810    
Inventories CZK mil                 145 193 185 230 263    
Receivables CZK mil                 264 268 356 357 403    
Cash & Cash Equivalents CZK mil                 50.0 11.0 71.2 6.99 0.936    
Total Assets CZK mil                 774 572 698 682 830    
Shareholders' Equity CZK mil                 460 289 286 243 246    
Of Which Minority Interest CZK mil                 0 0 0 0 0    
Liabilities CZK mil                 314 283 413 440 584    
Non-Current Liabilities CZK mil                 7.97 3.22 0 0 0    
Long-Term Debt CZK mil                 0 0 0 0 0    
Deferred Tax Liabilities CZK mil                 0 0 0 0 0    
Current Liabilities CZK mil                 306 280 410 426 522    
Short-Term Debt CZK mil                 0 0 90.1 28.5 151    
Trade Payables CZK mil                 210 146 188 230 204    
Provisions CZK mil                 3.92 0 0 12.1 61.9    
Equity And Liabilities CZK mil                 774 572 698 682 830    
growth rates                              
Total Asset Growth % ...               -41.7 -26.0 22.0 -2.28 21.7    
Shareholders' Equity Growth % ...               -6.69 -37.1 -1.31 -15.1 1.44    
Net Debt Growth % ...               -71.1 -78.0 -272 13.5 595    
Total Debt Growth % ... ... ... ... ... ...   ... ... ... ... -68.3 428    
ratios                              
Total Debt CZK mil                 0 0 90.1 28.5 151    
Net Debt CZK mil                 -50.0 -11.0 19.0 21.5 150    
Working Capital CZK mil                 199 315 353 356 463    
Capital Employed CZK mil                 270 345 371 371 479    
Net Debt/Equity %                 -10.9 -3.80 6.64 8.88 60.8    
Cost of Financing % ... ... ... ... ...     ... ... ... 11.0 6.28 1.76    
cash flow Unit 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
cash flow                              
Net Profit CZK mil                 166 83.4 96.2 107 123    
Depreciation CZK mil                 7.96 7.87 7.63 4.06 4.42    
Non-Cash Items CZK mil ...           ... ... ... ... ... ... ...    
Change in Working Capital CZK mil ...           ... ... ... ... ... ... ...    
Total Cash From Operations CZK mil             ... ... ... ... ... ... ...    
Capital Expenditures CZK mil             ... ... ... ... ... ... ...    
Other Investments CZK mil             ... ... ... ... ... ... ...    
Total Cash From Investing CZK mil             ... ... ... ... ... ... ...    
Dividends Paid CZK mil             ... ... ... ... ... ... ...    
Issuance Of Shares CZK mil ... ... ... ... ... ... ... ... ... ... ... ... ...    
Issuance Of Debt CZK mil ...           ... ... ... ... ... ... ...    
Total Cash From Financing CZK mil             ... ... ... ... ... ... ...    
Net Change In Cash CZK mil             ... ... ... ... ... ... ...    
ratios                              
Days Sales Outstanding days                 28.8 30.2 37.8 32.1 34.4    
Days Sales Of Inventory days                 15.8 24.6 22.6 23.6 26.1    
Days Payable Outstanding days                 22.9 18.6 23.0 23.7 20.2    
Cash Conversion Cycle days                 21.7 36.1 37.5 32.0 40.3    
Cash Earnings CZK mil                 174 91.3 104 111 128    
Free Cash Flow CZK mil             ... ... ... ... ... ... ...    
other data Unit 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
other data                              
ROA %                 15.8 12.4 15.1 15.5 16.3    
Gross Margin %                 0.050 11.5 13.1 12.3 13.8    
Employees                 184 170 178 181 187    
Cost Per Employee USD per month                 6,399 6,086 6,633 6,393 6,044    
Cost Per Employee (Local Currency) CZK per month                 113,170 119,036 129,773 136,628 144,259    
Staff Cost (As % Of Total Cost) %                 7.85 7.73 8.37 7.58 7.87    
Effective Tax Rate %                 14.9 18.2 21.7 20.9 23.8    
Domestic Sales CZK mil                 2,475 2,444 2,503 3,017 3,242    
Capital Expenditures (As % of Sales) %             ... ... ... ... ... ... ...    
Revenues From Abroad CZK mil                 17.0 24.0 23.2 1,037 1,034    
Revenues From Abroad (As % Of Total) %                 0.508 0.740 0.673 25.6 24.2    

Get all company financials in excel:

Download Sample   $19.99

Bayer, s.r.o. (or Bayer Czech Republic in our case) is a Czech Republic-based subsidiary of Bayer AG, the German chemical and pharmaceutical company founded in Barmen, Germany in 1863. It is headquartered in Leverkusen, North Rhine-Westphalia, Germany and well known for its original brand of aspirin. The Company is now a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. In fiscal year 2013, Bayer employed 113,200 people and had sales of EUR 40.2 bil.

Bayer Czech Republic Logo

Finance

Bayer Czech Republic has been growing its sales by a year on average in the last 5 years. EBITDA has grown on average by 7.04% a year during that time to total of CZK 158 mil in 2017, or 3.77% of sales. That’s compared to 4.11% average margin seen in last five years.

The company netted CZK 106 mil in 2017 implying ROE of 27.2% and ROCE of 10.4%. Again, the average figures were 41.9% and 23.7%, respectively when looking at the previous 5 years.

Bayer Czech Republic’s net debt amounted to CZK 393 mil at the end of 2017, or 94.4% of equity. When compared to EBITDA, net debt was 2.49x, up when compared to average of 1.13x seen in the last 5 years.

More Companies in Czech Pharmaceutical Sector

Helgi Library
Eliášova 38, Prague 6, 160 00, Czech Republic
Copyright © 2024 Helgi Library. All rights reserved.